



## REQUEST FOR QUOTATION No. 51/2017/M/GATE dated 14.12.2017

for CELON PHARMA SA with its registered office in Kiełpin

- As part of the project called “Preclinical and clinical development of an innovative GPR40 agonist in type II diabetes” under the “Smart Growth Operational Programme 2014-2020”,

Celon Pharma SA hereby invites to tender.

**DATE OF PUBLICATION: 14.12.2017**

**LOCATION:** Kiełpin

**ANNOUNCEMENT PUBLICATION:** obligatory

**ORDERING PARTY:** Celon Pharma SA, ul. Ogrodowa 2a, 05-092 Kiełpin

**OFFICIAL WEBSITE ADDRESS OF THE ORDERING PARTY**

**[www.celonpharma.com](http://www.celonpharma.com), telephone: 022 7515933**

**TYPE OF THE ORDERING PARTY:** Private entity

**A PARTIAL TENDER ALLOWED** YES

**A VARIANT TENDER ALLOWED** NO

**APPROXIMATE PURCHASING START DATE**

**Start date:** December 2017

**APPROXIMATE PURCHASING END DATE**

**End date:** December 2017

---

**CELON PHARMA S.A.**

Biuro: ul. Ogrodowa 2A, 05-092 Łomianki / Kiełpin,, Dział R&D: ul. Mokra 41A, 05-092 Łomianki / Kiełpin,  
tel.:+48 22 751 74 78; fax: +48 22 751 74 77 e-mail: [info@celonpharma.com](mailto:info@celonpharma.com), [www.celonpharma.com](http://www.celonpharma.com)

**Organ rejestrowy:** Sąd Rejonowy dla m. st. Warszawy, XIV Wydział Gospodarczy Krajowego Rejestru Gospodarczego

**Prezes Zarządu:** Maciej Wieczorek, **Wysokość kapitału zakładowego:** 4.500.000 PLN

**KRS:** 0000437778, **NIP :** 118 16 42 061



## PROCEDURE

### Request for quotation

#### CONTRACT AWARD PROCEDURE:

1. This contract award procedure is not governed by the provisions of the Act of 29 January 2004 – the Public Procurement Law.
2. This contract award procedure shall be conducted with due observance of the principles of competitiveness, openness, transparency and equal access.
3. The Ordering Party reserves itself the right to nullify the procedure at any stage thereof without stating the reason.
4. The Ordering Party shall inform Suppliers about any changes made by publishing relevant information on its website.
5. The Ordering Party reserves itself the right to request additional information, documents or explanations.
6. In justified cases, at any time before the expiry of the deadline for the submission of tenders, Celon Pharma SA may modify or supplement the content of the invitation to tender.
7. This invitation to tender imposes no obligation on Celon Pharma SA to conclude a contract.

#### DETAILS CONCERNING THE OBJECT OF A CONTRACT:

CPV codes: 24000000-4

#### OBJECT OF THE REQUEST FOR QUOTATION No. 51/2017/M/GATE

#	GOODS	PACK SIZE	QUANTITY
1	4-(4-Ethynylbenzenesulfonyl)-piperazine-1-carboxylic acid tert-butyl ester (e.g. cat. No Combi Blocks QB-8772 or equivalent)	1g	1
2	1-Boc-4-ethynylpiperidine (e.g. cat. No Combi Blocks QA-7125 or equivalent)	5g	1
3	4-Ethynyl-1H-pyrazole (e.g. cat. No Combi Blocks QE-2486 or equivalent)	1g	1

---

#### CELON PHARMA S.A.

Biuro: ul. Ogrodowa 2A, 05-092 Łomianki / Kiełpin,, Dział R&D: ul. Mokra 41A, 05-092 Łomianki / Kiełpin,  
tel.:+48 22 751 74 78; fax: +48 22 751 74 77 e-mail: info@celonpharma.com, [www.celonpharma.com](http://www.celonpharma.com)

**Organ rejestrowy:** Sąd Rejonowy dla m. st. Warszawy, XIV Wydział Gospodarczy Krajowego Rejestru Gospodarczego

**Prezes Zarządu:** Maciej Wieczorek, **Wysokość kapitału zakładowego:** 4.500.000 PLN

**KRS:** 0000437778, **NIP :** 118 16 42 061



4	5-Ethynyl-1h-pyrazole (e.g. cat. No Combi Blocks QH-8196 or equivalent)	250mg	1
5	[(4-Cyano-2-fluorophenyl)methyl]boronic acid (e.g. cat. No Combi Blocks BB-0087 or equivalent)	1g	1

1. Due to the continuation of research work as part of the said project, its specificity and unique nature, and the fact that reagents/materials used in the research process will have a significant impact on the shape of the conducted R&D work, for technical reasons of an objective nature, the description of the object of a contract indicates the reference number of the product(s).
2. Due to the uniqueness, unprecedented nature and precisely defined methodology of the conducted projects, research and experiments, as well as the necessity to maintain the continuity and repeatability of studies conducted by the Ordering Party, each Supplier offering products equivalent to the products described in the request for quotation shall be obliged:
  - to prove, on the basis of technical documentation/safety data sheets for reagents etc., and a written declaration, that the offered equivalent products (each of such products separately) meet the requirements allowing the continuation of research by the Purchaser with no need to perform additional activities (procedures), including, for example, calibration of devices or validation of the developed laboratory methods,
  - to prove (by way of a written declaration included in the submitted tender) that the offered equivalent products will not cause any increase in costs due to the need to purchase additional products and other consumables,
  - to assume liability – in the form of a written declaration – for any damage to equipment caused due to the use of the equivalent products offered and delivered, according to the opinion issued by an authorised repairer of the equipment manufacturer.
3. The Supplier shall pay contractual penalties to the Ordering Party:
  - for any delay in the delivery of the object of a contract, for each started day of such delay, unless the delay is caused due to the Purchaser's fault,
  - if the results of studies conducted with the use of the equivalent product do not satisfy the expectations,
  - the Supplier expresses its consent to contractual penalties being deducted directly from the invoice amount at the time of payment of the VAT invoice related to the completion of the delivery.

---

**CELON PHARMA S.A.**

Biuro: ul. Ogrodowa 2A, 05-092 Łomianki / Kiełpin,, Dział R&D: ul. Mokra 41A, 05-092 Łomianki / Kiełpin,  
tel.:+48 22 751 74 78; fax: +48 22 751 74 77 e-mail: info@celonpharma.com, [www.celonpharma.com](http://www.celonpharma.com)

**Organ rejestrowy:** Sąd Rejonowy dla m. st. Warszawy, XIV Wydział Gospodarczy Krajowego Rejestru Gospodarczego

**Prezes Zarządu:** Maciej Wieczorek, **Wysokość kapitału zakładowego:** 4.500.000 PLN

**KRS:** 0000437778, **NIP :** 118 16 42 061



**TENDER EVALUATION CRITERIA:**

- Price 60%
- Lead time 40%

**POINT SCORING SYSTEM:**

$$(x/y)*60 \text{ or } 40$$

where:

- X – lowest price,
- Y – evaluated price,

Criterion	Weight [%]	Points	Evaluation formula
Price	60%	60	$C = \frac{\text{Lowest quoted price}}{\text{Quoted price}} \times 60 \text{ points}$
Lead time	40%	40	$D = \frac{\text{Shortest offered lead time}}{\text{Offered lead time}} \times 40 \text{ points}$
<b>Total</b>	100%	100	

**Address and deadline for the submission of tenders:**

1. Tenders must be submitted to the Ordering Party to the address of its registered office: ul. Główna 48, 05-152 Kazuń Nowy, Poland, if sent by traditional or courier mail, or to the e-mail address: [paulina.gruszka@celonpharma.com](mailto:paulina.gruszka@celonpharma.com) , if sent by electronic mail.
2. Tenders must be submitted on **21.12.2017** at the latest. If a tender is sent by traditional or courier mail, it shall be deemed submitted on the day of its delivery to the registered office of the Ordering Party.
3. Tenders submitted after the expiry of the deadline shall not be processed.
4. Tenders shall be evaluated at the registered office of the Ordering Party by **22.12.2017** at the latest.

**CELON PHARMA S.A.**

Biuro: ul. Ogrodowa 2A, 05-092 Łomianki / Kiełpin,, Dział R&D: ul. Mokra 41A, 05-092 Łomianki / Kiełpin,  
tel.:+48 22 751 74 78; fax: +48 22 751 74 77 e-mail: [info@celonpharma.com](mailto:info@celonpharma.com), [www.celonpharma.com](http://www.celonpharma.com)

**Organ rejestrowy:** Sąd Rejonowy dla m. st. Warszawy, XIV Wydział Gospodarczy Krajowego Rejestru Gospodarczego

**Prezes Zarządu:** Maciej Wieczorek, **Wysokość kapitału zakładowego:** 4.500.000 PLN

**KRS:** 0000437778, **NIP :** 118 16 42 061



## Presentation of tenders:

1. Each Tenderer may submit only one tender. The tender must include the following details:
  - a. the number of the request for quotation,
  - b. the date of preparation,
  - c. the details of the Tenderer: address, telephone number, e-mail address, Tax Identification Number (NIP) (if available),
  - d. detailed information about the compliance of the proposed device with the specification.
2. The tender must be submitted along with the “Declaration of no personal or capital connections with the Ordering Party”.
3. The number of the request for quotation must also appear in the titles of e-mail messages, traditional or courier mail.
4. The tender must remain valid for at least ..... months after the expiry of the deadline for the submission of tenders.
5. The tender preparation costs shall be borne by the Tenderer.
6. The tender must be initialled and signed by persons authorised to represent the Economic Operator/Supplier.

## VII. NOTIFICATION OF THE CONTRACT AWARD

Information about the result of the contract award procedure shall be sent to each economic operator that submitted the tender, and it shall be published on the website at [www.celonpharma.com](http://www.celonpharma.com).

**PLEASE SUBMIT TENDERS PROVIDING FOR PAYMENT BASED ON INVOICES WITH AT LEAST A 30-DAY TIME LIMIT FOR PAYMENT.**

---

### CELON PHARMA S.A.

Biuro: ul. Ogrodowa 2A, 05-092 Łomianki / Kiełpin,, Dział R&D: ul. Mokra 41A, 05-092 Łomianki / Kiełpin,  
tel.:+48 22 751 74 78; fax: +48 22 751 74 77 e-mail: [info@celonpharma.com](mailto:info@celonpharma.com), [www.celonpharma.com](http://www.celonpharma.com)

**Organ rejestrowy:** Sąd Rejonowy dla m. st. Warszawy, XIV Wydział Gospodarczy Krajowego Rejestru Gospodarczego

**Prezes Zarządu:** Maciej Wieczorek, **Wysokość kapitału zakładowego:** 4.500.000 PLN

**KRS:** 0000437778, **NIP :** 118 16 42 061